Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, fluoxetine 58% Improvement Relative Risk Progression, fluoxetine 45% Progression, fluoxetine (b) 11% Mortality, all SSRIs -32% Progression, all SSRIs -22% Progression, all SSRIs (b) -7% c19early.org/f Stauning et al. Fluvoxamine for COVID-19 Prophylaxis Is prophylaxis with fluvoxamine beneficial for COVID-19? Retrospective 286,447 patients in Denmark (February 2020 - October 2021) Lower mortality (p=0.39) and progression (p=0.3), not stat. sig. Stauning et al., Clinical Microbiology and Infec.., doi:10.1016/j.cmi.2023.04.028 Favors fluvoxamine Favors control

COVID-19 mortality among selective serotonin reuptake inhibitor users - Results from a nationwide cohort

Stauning et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2023.04.028
Stauning et al., COVID-19 mortality among selective serotonin reuptake inhibitor users - Results from a nationwide cohort, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2023.04.028
May 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 7,113 COVID+ SSRI users and 279,334 COVID+ non-SSRI users in Denmark, showing lower mortality with fluoxetine, without statistical significance, but higher mortality for other SSRIs.
risk of death, 57.7% lower, HR 0.42, p = 0.39, NNT 182, adjusted per study, odds ratio converted to relative risk, fluoxetine, multivariable, Cox proportional hazards.
risk of progression, 44.5% lower, HR 0.55, p = 0.30, adjusted per study, odds ratio converted to relative risk, fluoxetine, severe acute respiratory syndrome or death, multivariable, Cox proportional hazards.
risk of progression, 10.8% lower, HR 0.89, p = 0.84, adjusted per study, odds ratio converted to relative risk, fluoxetine, severe acute respiratory syndrome, multivariable, Cox proportional hazards.
risk of death, 31.6% higher, HR 1.32, p = 0.01, adjusted per study, odds ratio converted to relative risk, all SSRIs, multivariable, Cox proportional hazards.
risk of progression, 22.5% higher, HR 1.22, p < 0.001, adjusted per study, odds ratio converted to relative risk, all SSRIs, severe acute respiratory syndrome or death, multivariable, Cox proportional hazards.
risk of progression, 6.9% higher, HR 1.07, p = 0.40, adjusted per study, odds ratio converted to relative risk, all SSRIs, severe acute respiratory syndrome, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Stauning et al., 5 May 2023, retrospective, Denmark, peer-reviewed, mean age 50.4, 4 authors, study period 26 February, 2020 - 5 October, 2021.
Contact: marius.ahm.stauning@regionh.dk.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFluvoxamineAll
Abstract: Journal Pre-proof COVID-19 mortality among selective serotonin reuptake inhibitor users - Results from a nationwide cohort Marius Ahm Stauning, Dogukan Jesper Gür, Christian Torp-Pedersen, Jens Tingleff PII: S1198-743X(23)00203-3 DOI: https://doi.org/10.1016/j.cmi.2023.04.028 Reference: CMI 3282 To appear in: Clinical Microbiology and Infection Received Date: 3 January 2023 Revised Date: 25 March 2023 Accepted Date: 26 April 2023 Please cite this article as: Stauning MA, Gür DJ, Torp-Pedersen C, Tingleff J, COVID-19 mortality among selective serotonin reuptake inhibitor users - Results from a nationwide cohort Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2023.04.028. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2023 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. Titlepage Original article: COVID-19 mortality among selective serotonin reuptake inhibitor users Results from a nationwide cohort re -p r oo f Marius Ahm Stauning 1 * Dogukan Jesper Gür 2 * Christian Torp-Pedersen3, 4 Jens Tingleff 2, 5 ur na lP 1) Department of Clinical Microbiology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark 2) Department of Emergency Medicine, Copenhagen University Hospital - Amager and Hvidovre , Copenhagen, Denmark 3) Department of Cardiology, Copenhagen University Hospital – North Zealand, Hillerød, Denmark. 4) Department of Public Health, University of Copenhagen, Denmark 5) Department of Clinical Medicine, University of Copenhagen, Denmark. Jo *) These authors contributed equally to the study and share first authorship. Corresponding author: Marius Ahm Stauning, M.D Department of Clinical Microbiology, Copenhagen University Hospital – Rigshospitalet Blegdamsvej 9, 2100 Copenhagen Denmark Email: marius.ahm.stauning@regionh.dk Phone: +45 60 89 88 23 Abstract Objective: To examine differences in mortality and/or severe acute respiratory syndrome between selective serotonin reuptake inhibitor- (SSRI) users and non-SSRI-users up to 60 days after a positive severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) real-time reverse transcription-polymerase chain reaction (PCR) test. Methods: Retrospective cohort study including all Danish residents above the age of eighteen with oo f a positive SARS- CoV-2 PCR test from February 26th, 2020, to October 5th2021. The follow-up re -p r period was 60 days. The primary outcome was all-cause mortality, and the secondary outcome was severe acute respiratory syndrome. Exposure of interest was SSRI-use. Differences between SSRI- lP users and non-users were examined with Cox Regression. ur na Results: 286447 SARS-CoV-2 positive individuals were identified, and 7113 met the criteria for SSRI-use. SSRI-users had a mean age of 50.4 years, and 34% were male. Non-SSRI users had a mean age of 41.4 years, and 50 % were male. Similar vaccination frequency was seen..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit